3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Renal Insufficiency
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Leukemia
1
Kidney Neoplasms
1
Hematologic Diseases
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Blood Protein Disorders
1
Interventions
Cyclophosphamide
30
fludarabine phosphate
19
Peripheral Blood Stem Cell Transplantation
18
Tacrolimus
17
Mycophenolic Acid
16
Methotrexate
16
Whole-Body Irradiation
14
Etoposide
13
Vincristine
12
Doxorubicin
12
Dexamethasone
11
Busulfan
11
Cytarabine
10
Antilymphocyte Serum
10
venetoclax
9
Prednisone
9
nelarabine
8
Rituximab
8
Filgrastim
8
Cyclosporine
8
Calcium Dobesilate
8
merphos
7
Melphalan
7
Radiotherapy
6
prednylidene
5
deltacortene
5
Methylprednisolone
5
Azacitidine
5
Sirolimus
4
Granulocyte Colony-Stimulating Factor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
Ranitidine
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts